Itolizumab

Itolizumab

Itolizumab (pronounced as i-to-li-zu-mab) is a monoclonal antibody specifically designed for the treatment of various autoimmune diseases and inflammatory conditions. It is a humanized antibody that targets the CD6 molecule, a protein present on the surface of T cells, which are a type of white blood cell.

Etymology

The name "Itolizumab" is derived from the combination of "ito", an abbreviation for "immunomodulatory", "li", short for "linker", and "zumab", a common suffix for humanized monoclonal antibodies.

Usage

Itolizumab is used in the treatment of psoriasis, a chronic skin condition, and has been approved for emergency use in the treatment of cytokine release syndrome (CRS) in patients with moderate to severe COVID-19 symptoms. It works by suppressing the immune response, thereby reducing inflammation and improving symptoms.

Related Terms

• Monoclonal Antibody
• Autoimmune Diseases
• Inflammatory Conditions
• CD6
• Psoriasis
• COVID-19
• Cytokine Release Syndrome

See Also

• List of monoclonal antibodies
• Immunosuppressive drug
• Biologic therapy

External links

• Medical encyclopedia article on Itolizumab
• Wikipedia's article - Itolizumab

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski